Last reviewed · How we verify
Quadruple therapy
Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors.
Quadruple therapy combines four antiviral agents to simultaneously target multiple stages of viral replication and host factors. Used for Chronic hepatitis C virus (HCV) infection.
At a glance
| Generic name | Quadruple therapy |
|---|---|
| Also known as | Moxiflox, Downoprazol, Nanazoxid, Doxymycin, Esomeprazole (Nexium) 20mg bid, Metronidazole (Flagyl) 400mg qid, Bismuth subcitrate 120mg qid, Tetracycline 500mg qid |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Antiviral combination therapy |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
This regimen typically combines direct-acting antivirals (DAAs) with different mechanisms of action to inhibit viral protease, polymerase, and NS5A functions, while potentially including an immunomodulatory component. The multi-targeted approach reduces the likelihood of resistance development and improves sustained virological response rates.
Approved indications
- Chronic hepatitis C virus (HCV) infection
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (PHASE3)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma (PHASE1, PHASE2)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |